DNAe, understanding tech and business

News

The liquidity paradox of the 505(b)(2) drug development pathway

Outcome Capital highlights a critical dynamic shaping biopharma investment strategy: the liquidity paradox of the 505(b)(2) pathway. In a recent article published in Cell Press Trends in Biotechnology, Managing Partner Oded Ben-Joseph, PhD and Managing Director Stanislav Glezer, MD, MBA examine why more efficient development does not always translate into stronger or earlier liquidity outcomes, […]

Read More
Resources

Outcome Capital Life Science Market Pulse

Outcome Capital Life Science Market Pulse February 2026 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis